Evidence map›Paper›PMID 38547418›Full record

ArticleJCO precision oncology2024

Human Epidermal Growth Factor Receptor 2-Low Breast Cancer Brain Metastases: An Opportunity for Targeted Systemic Therapies in a High-Need Patient Population.

Rania Chehade, Sharon Nofech-Mozes, Anna Plotkin, Kevin Yijun Fan, Sunit Das, Arjun Sahgal, Veronika Moravan, Katarzyna Joanna Jerzak

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO precision oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Effect of HER2-low status on brain metastasis-free survival and survival after brain metastasis in patients with breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Rania ChehadeFaculty of Medicine, Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada.
Sharon Nofech-MozesPrecision Diagnostics and Therapeutics Program Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Anna PlotkinPrecision Diagnostics and Therapeutics Program Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Kevin Yijun FanFaculty of Medicine, University of Toronto, Toronto, ON, Canada.ORCID 0000-0002-8233-5626
Sunit DasFaculty of Medicine, Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada.ORCID 0000-0002-2146-4168
Arjun SahgalSunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Veronika MoravanVM Stats, Toronto, ON, Canada.
Katarzyna Joanna JerzakFaculty of Medicine, Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada.ORCID 0000-0002-3995-0308
Sunnybrook Health Science Centre · CAStatistics Canada · CASt. Michael's Hospital · CAUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTrastuzumab deruxtecan is a new treatment option for patients with advanced human epidermal growth factor receptor 2 (HER2)-low breast cancer (BC). Although HER2-low status has been characterized in early and advanced BC, it has yet to be fully characterized in brain metastases (BrM).

methodsPatients who underwent surgery for BC BrM at Sunnybrook Health Sciences Centre and for whom HER2 status was available on resected BrM were studied. Estrogen receptor, progesterone receptor, and HER2 status were assessed on the basis of ASCO/College of American Pathologists (CAP) guidelines. HER2-zero was defined as immunohistochemistry (IHC) 0; HER2-low was defined as IHC 1+ or IHC 2+ with fluorescence in situ hybridization (FISH)-negative status. HER2-positive (HER2+) was defined as IHC 3+ or IHC 2+ with positive FISH. Clinicopathologic features were recorded. We also assessed the prognostic association between extent of HER2 expression and (1) brain-specific progression-free survival (bsPFS), as well as (2) overall survival (OS).

resultsIn this retrospective cohort of 102 patients with resected BC BrM, 53% (n = 54) were HER2+, 29.4% (n = 30) were HER2-low, and 17.6% (n = 18) had HER2-zero status. Among BrM that were triple-negative on the basis of ASCO/CAP guidelines, 63.6% (n = 14/22) were reclassified as being HER2-low. Sixty percent (n = 15/25) of BrM that were hormone receptor-positive/HER2-negative (HR+/HER2-) were reclassified as being HER2-low. In total, 51 patients had matched primary breast and BrM tissue available; results of HER2 status when categorized as HER2-zero, HER2-low, and HER2+ were concordant in 82.3% (n = 42/51) of cases (Cohen's kappa, 0.58;

conclusionAmong patients with surgically resected BrM, a high proportion of those with metastatic triple-negative BC and HR+/HER2- disease have HER2-low BrM with potential to benefit from HER2-targeted therapy.

Indexed as

Brain NeoplasmsBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesMolecular Targeted TherapyFemaleHumansIn Situ Hybridization, FluorescenceRetrospective StudiesERBB2 protein, humanErb-b2 Receptor Tyrosine Kinases

Identifiers

PMID38547418
PMCPMC10994430
OpenAlexW4393282846

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.